http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 05 Jan 2026 13:08:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Press+Releases/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html <p align="start">VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0hXIMIpYSHST1QH1KeXK2DfMhdgf-xRUX1W5ZbtCVh9AhNAt-Gp_UaSRvWEhzBfU4fTVGe5iTjDIhLKkNrASE4QVXoqNjKz7nQUgsnysQG1yyzSSfQL1sVe0yBxEYUOH63OphpWalFFuSaSiEBmv5xxzpZVRy9f8Pss6B3LCthU=" rel="nofollow" target="_blank">FITY</a>) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. Arora had seen Fifty1 Labs through a period of transition until http://www.streetinsider.com/Globe+Newswire/Fifty1+Labs%2C+Inc.+Clarifies+Status+Regarding+Previously+Announced+Collaboration+with+LUNR+Aerospace/25803632.html Mon, 05 Jan 2026 13:08:00 -0500 A.50204478 FITY O.00079437 O.01303741 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Press+Releases/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156 http://www.streetinsider.com/Globe+Newswire/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html <p align="left">VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=zfZ1-h50Vb4GUNSbQuiapDY6Obi0kWkseRv9noQJ4POBqxXuYrTJigX39mcnelsTcO9oLdUN2V2YJGOhNTqlBmhfcTxjKjb9FVDFRZRIMRV5sbstuIC-G11IB0F1QU6HsD2C_gkkP-LevTRigdAV-PJzLP0-kvEJOn2wJksOkAo=" rel="nofollow" target="_blank">FITY</a>) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs&apos; commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.</p> <p align="start">Dr. Gagnier brings highly credentialed http://www.streetinsider.com/Globe+Newswire/Fifty+1+Labs+Inc.+Appoints+Dr.+Joel+Gagnier+as+Chief+Science+Officer/25439107.html Thu, 09 Oct 2025 10:23:00 -0500 A.00608379 A.10141387 A.30990673 A.32526562 A.42668003 A.50204478 A.60012013 FITY O.00079437 O.00449131 O.00785300 O.01303741 O.20059298 O.32222810 O.38345417 O.54379156